Home > Boards > US OTC > Biotechs > Inspyr Therapeutics Inc. (NSPX)

Royal Society of Chemistry -"In addition to

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Goodmooring Member Profile
 
Followed By 2
Posts 286
Boards Moderated 1
Alias Born 01/02/18
160x600 placeholder
Goodmooring   Tuesday, 10/08/19 10:46:45 AM
Re: None
Post # of 9200 
Royal Society of Chemistry -"In addition to its physiological importance, SERCA is the
target for Mipsagargin (G202), a drug candidate for treatment
of prostate cancer and hepatocellular carcinoma derived from
the natural product thapsigargin (TG)"

https://pubs.rsc.org/en/content/articlelanding/2019/cp/c9cp04736k#!divAbstract
The article was received on 26 Aug 2019, accepted on 17 Sep 2019 and first published on 17 Sep 2019

$NSPX STONGER

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist